Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

The functions of natural killer (NK) and T cells in innate and adaptive immunity, as well as
their functions in tumor eradication, are complementary and intertwined. Here we show that …

Antibody-drug conjugates (ADCs) enable the precise delivery of cytotoxic agents by
conjugating small-molecule drugs with monoclonal antibodies (mAbs). Over recent decades …

Bispecific antibodies as T cell engagers designed to display binding capabilities to both
tumor-associated antigens and antigens on T cells are considered promising agents in the …

Polyethylene glycol (PEG)-modified nanoparticles (NPs) often struggle with reduced
effectiveness against metastasis and liquid tumors due to limited tumor cell uptake and …

Antibodies and their derivatives (scFv, Fabs, etc.) represent a unique class of biomolecules
that combine selectivity with the ability to target drug delivery. Currently, one of the most …

Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors
(ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies …

In this study, an amphiphilic polymer (Bio-HA (TPE-CN)-mPEG) was designed and
synthesized, which was fabricated by introducing hydrophobic aggregation-induced …

MicroRNAs (miRNA) mediate cell phenotype and tumor progression across various tissue
types, acting via post-transcriptional repression of gene expression. Pre-clinical evidence …